ReviewInternational journal of heart failure2020
Optimization of Heart Failure Treatment by Heart Rate Reduction.
Review in International journal of heart failure, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Rethinking atrial pacing support in cardiac resynchronization therapy: insights from the CRT-NEXT trial.Heart failure reviews · 2026Article
- Comparative Effectiveness of Ivabradine versus Digoxin in Patients with Heart Failure with Reduced Ejection Fraction and Chronic Kidney Disease: A Real-World Multicenter Cohort Study.Cardiorenal medicine · 2026Article
- Resting heart rate as an independent predictor of major adverse cardiovascular events in patients receiving maintenance hemodialysis: a prospective cohort study.Frontiers in medicine · 2026Article
- Identifying patients' signs and symptoms to guide eHealth-directed diuretic therapy intensification in heart failure-Insights from the trial of intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF).Wiener klinische Wochenschrift · 2025Article
- Comparison Between Water Aerobics and Deep-Water Running on Middle-Aged Adults' Anthropometric, Hemodynamic and Functional Outcomes.International journal of environmental research and public health · 2025Article
- Article
- Heart Rate Reduction and Outcomes in Heart Failure Outpatients.Journal of clinical medicine · 2023Article
- Optimization of guideline-directed medical treatment for heart failure patients with reduced ejection fraction.The Korean journal of internal medicine · 2023Review
- Is there any difference in the therapeutic effects of Levosimendan on advanced HFrEF patients with sinus rhythm or atrial fibrillation?Frontiers in cardiovascular medicine · 2023Article
- Stroke Severity in Ischemic Stroke Patients with a History of Diastolic Blood Pressure Treated in a Telestroke Network.Journal of cardiovascular development and disease · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure (HF) treatment should be optimized in addition to guideline-directed and recommended drugs to achieve an appropriate heart rate (i.e. 50-60 bpm) by ivabradine in patients with a heart rate >70 bpm in sinus rhythm and with an ejection fraction ≤35%. Heart rate reduction was to reduce cardiovascular death and HF hospitalization dependent on baseline resting heart rate. In particular in patients at a heart rate >75 bpm, a reduction in cardiovascular death, all-cause death, HF death, HF hospitalization and all-cause hospitalization has been observed. The optimal heart rate achieved appears to be between 50-60 bpm, if well tolerated as in these patients the lowest event rate is observed on treatment. Heart rate reduction is, therefore, a treatable risk factor in chronic HF. Observational studies support the concept that it is a risk indicator in other cardiovascular and non-cardiovascular conditions. Whether heart rate reduction is also modifying risk in other conditions than chronic HF should be explored in prospective clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.